258 related articles for article (PubMed ID: 15503665)
1. Toxicogenomic approach to endocrine disrupters: identification of a transcript profile characteristic of chemicals with estrogenic activity.
Naciff JM; Daston GP
Toxicol Pathol; 2004; 32 Suppl 2():59-70. PubMed ID: 15503665
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profile induced by 17alpha-ethynyl estradiol, bisphenol A, and genistein in the developing female reproductive system of the rat.
Naciff JM; Jump ML; Torontali SM; Carr GJ; Tiesman JP; Overmann GJ; Daston GP
Toxicol Sci; 2002 Jul; 68(1):184-99. PubMed ID: 12075121
[TBL] [Abstract][Full Text] [Related]
4. Species-specific considerations in using the fish embryo test as an alternative to identify endocrine disruption.
Schiller V; Zhang X; Hecker M; Schäfers C; Fischer R; Fenske M
Aquat Toxicol; 2014 Oct; 155():62-72. PubMed ID: 24992288
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of a Tier I screening battery compared to an in utero exposure for detecting the estrogen receptor agonist 17 beta-estradiol.
O'Connor JC; Frame SR; Biegel LB; Cook JC; Davis LG
Toxicol Sci; 1998 Aug; 44(2):169-84. PubMed ID: 9742655
[TBL] [Abstract][Full Text] [Related]
6. Environmental signaling: from environmental estrogens to endocrine-disrupting chemicals and beyond.
McLachlan JA
Andrology; 2016 Jul; 4(4):684-94. PubMed ID: 27230799
[TBL] [Abstract][Full Text] [Related]
7. Novel progestogenic activity of environmental endocrine disruptors in the upregulation of calbindin-D9k in an immature mouse model.
Jung YW; Hong EJ; Choi KC; Jeung EB
Toxicol Sci; 2005 Jan; 83(1):78-88. PubMed ID: 15509668
[TBL] [Abstract][Full Text] [Related]
8. FIFRA Subdivision F testing Guidelines: are these tests adequate to detect potential hormonal activity for crop protection chemicals? Federal Insecticide, Fungicide, and Rodenticide Act.
Stevens JT; Tobia A; Lamb JC; Tellone C; O'Neal F
J Toxicol Environ Health; 1997 Apr; 50(5):415-31. PubMed ID: 9140462
[TBL] [Abstract][Full Text] [Related]
9. Assessment of total effective xenoestrogen burden in adipose tissue and identification of chemicals responsible for the combined estrogenic effect.
Fernández MF; Rivas A; Olea-Serrano F; Cerrillo I; Molina-Molina JM; Araque P; Martínez-Vidal JL; Olea N
Anal Bioanal Chem; 2004 May; 379(1):163-70. PubMed ID: 15024544
[TBL] [Abstract][Full Text] [Related]
10. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
11. Is exposure to environmental or industrial endocrine disrupting estrogen-like chemicals able to cause genomic instability?
Roy D; Colerangle JB; Singh KP
Front Biosci; 1998 Aug; 3():d913-21. PubMed ID: 9696883
[TBL] [Abstract][Full Text] [Related]
12. The endocrine and reproductive system: adverse effects of hormonally active substances?
Greim HA
Pediatrics; 2004 Apr; 113(4 Suppl):1070-5. PubMed ID: 15060201
[TBL] [Abstract][Full Text] [Related]
13. Tiered screening and testing strategy for xenoestrogens and antiandrogens.
Gray LE
Toxicol Lett; 1998 Dec; 102-103():677-80. PubMed ID: 10022334
[TBL] [Abstract][Full Text] [Related]
14. Comparative responses of three rat strains (DA/Han, Sprague-Dawley and Wistar) to treatment with environmental estrogens.
Diel P; Schmidt S; Vollmer G; Janning P; Upmeier A; Michna H; Bolt HM; Degen GH
Arch Toxicol; 2004 Apr; 78(4):183-93. PubMed ID: 14689164
[TBL] [Abstract][Full Text] [Related]
15. Ethical review of regulatory toxicology guidelines involving experiments on animals: the example of endocrine disrupters.
Purchase IF
Toxicol Sci; 1999 Dec; 52(2):141-7. PubMed ID: 10630565
[TBL] [Abstract][Full Text] [Related]
16. Effect of estrogenic binary mixtures in the yeast estrogen screen (YES).
Ramirez T; Buechse A; Dammann M; Melching-Kollmuß S; Woitkowiak C; van Ravenzwaay B
Regul Toxicol Pharmacol; 2014 Oct; 70(1):286-96. PubMed ID: 25017362
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds.
Boehme K; Simon S; Mueller SO
Toxicol Appl Pharmacol; 2009 Apr; 236(1):85-96. PubMed ID: 19371625
[TBL] [Abstract][Full Text] [Related]
18. An integrated "4-phase" approach for setting endocrine disruption screening priorities--phase I and II predictions of estrogen receptor binding affinity.
Shi L; Tong W; Fang H; Xie Q; Hong H; Perkins R; Wu J; Tu M; Blair RM; Branham WS; Waller C; Walker J; Sheehan DM
SAR QSAR Environ Res; 2002 Mar; 13(1):69-88. PubMed ID: 12074393
[TBL] [Abstract][Full Text] [Related]
19. Development of a Tier I screening battery for detecting endocrine-active compounds (EACs).
Cook JC; Kaplan MA; Davis LG; O'Connor JC
Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):60-8. PubMed ID: 9339481
[TBL] [Abstract][Full Text] [Related]
20. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT
Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
